The U.S. Food and Drug Administration (FDA) has green lighted Can-Fite’s plan to include children with psoriasis in studies of Piclidenoson, a small molecule, adenosine A3 receptor (A3AR) agonist.
The Pediatric Study Plan would allow enrollment of children with psoriasis to Can-Fite’s upcoming Phase 3 pivotal clinical psoriasis studies, aiming at registration of Piclidenoson with both the FDA and the European Medicines Agency (EMA) for the treatment of plaque psoriasis.
“We believe Piclidenoson’s oral formulation with its excellent safety profile, combined with its progressive effectiveness over time make it ideally suited for the chronic treatment of psoriasis in adults and children alike,” says Can-Fite VP Drug Development Dr. William Kerns in a news release.
